<code id='95B6679FAC'></code><style id='95B6679FAC'></style>
    • <acronym id='95B6679FAC'></acronym>
      <center id='95B6679FAC'><center id='95B6679FAC'><tfoot id='95B6679FAC'></tfoot></center><abbr id='95B6679FAC'><dir id='95B6679FAC'><tfoot id='95B6679FAC'></tfoot><noframes id='95B6679FAC'>

    • <optgroup id='95B6679FAC'><strike id='95B6679FAC'><sup id='95B6679FAC'></sup></strike><code id='95B6679FAC'></code></optgroup>
        1. <b id='95B6679FAC'><label id='95B6679FAC'><select id='95B6679FAC'><dt id='95B6679FAC'><span id='95B6679FAC'></span></dt></select></label></b><u id='95B6679FAC'></u>
          <i id='95B6679FAC'><strike id='95B6679FAC'><tt id='95B6679FAC'><pre id='95B6679FAC'></pre></tt></strike></i>

          leisure time

          leisure time

          author:knowledge    Page View:194
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Chemotherapy shortages won’t get better under Biden’s latest plan
          Chemotherapy shortages won’t get better under Biden’s latest plan

          PresidentBidenspokeaboutsupplychainresilienceanddrugshortages.AlexWong/GettyImagesWASHINGTON—Preside

          read more
          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more

          CMS should re

          AdobeIn2011,theCentersforMedicareandMedicaidServicescreatedtheannualwellnessvisit(AWV),anewvisittype